Search Results - "Dahlöf, Bjorn"

Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension by Rothwell, Peter M, Prof, Howard, Sally C, DPhil, Dolan, Eamon, MRCP, O'Brien, Eoin, Prof, Dobson, Joanna E, MSc, Dahlöf, Bjorn, Prof, Sever, Peter S, Prof, Poulter, Neil R, FMedSci

“…Summary Background The mechanisms by which hypertension causes vascular events are unclear. Guidelines for diagnosis and treatment focus only on underlying…”
Get full text

Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke by Rothwell, Peter M, FMedSci, Howard, Sally C, DPhil, Dolan, Eamon, MRCP, O'Brien, Eoin, FRCP, Dobson, Joanna E, MSc, Dahlöf, Bjorn, MD, Poulter, Neil R, FMedSci, Sever, Peter S, FRCP

“…Summary Background Analyses of some randomised trials show that calcium-channel blockers reduce the risk of stroke more than expected on the basis of mean…”
Get full text

Regression of ECG-LVH is Associated with Lower Risk of New-Onset Heart Failure and Mortality in Patients with Isolated Systolic Hypertension; The LIFE Study by LARSTORP, Anne Cecilie K, OKIN, Peter M, DEVEREUX, Richard B, OLSEN, Michael H, IBSEN, Hans, DAHLÖF, Bjorn, KJELDSEN, Sverre E, WACHTELL, Kristian

“…Hypertension and electrocardiographic left ventricular hypertrophy (ECG-LVH) are strong predictors of heart failure (HF). It is unclear whether regression of…”
Get full text

In-treatment stroke volume predicts cardiovascular risk in hypertension by Lønnebakken, Mai T, Gerdts, Eva, Boman, Kurt, Wachtell, Kristian, Dahlöf, Björn, Devereux, Richard B

“…OBJECTIVETo evaluate whether lower stroke volume during antihypertensive treatment is a predictor of cardiovascular events independent of left ventricular…”
Get full text

Cardiovascular Disease Risk Factors: Epidemiology and Risk Assessment by Dahlöf, Björn, MD

“…Current epidemiologic predictions show that the world is heading for a vascular tsunami of pandemic proportions. The number of people at high risk from…”
Get full text

Physical activity and exercise lower blood pressure in individuals with hypertension: narrative review of 27 RCTs by Börjesson, Mats, Onerup, Aron, Lundqvist, Stefan, Dahlöf, Björn

“…Regular physical activity (PA) reduces the blood pressure (BP) of individuals with hypertension. The present review analysed the scientific evidence for the BP…”
Get more information

Different Time Course for Prevention of Coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA) by Sever, Peter S., Poulter, Neil R., Dahlöf, Björn, Wedel, Hans

“…The lipid-lowering properties of statins reduce rates of coronary artery disease (CAD) events and strokes. Findings of recently conducted, longitudinal…”
Get full text

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase by Gupta, Ajay, MRCP, Thompson, David, MRCPI, Whitehouse, Andrew, MBBS, Collier, Tim, MSc, Dahlof, Bjorn, MD, Poulter, Neil, Prof, Collins, Rory, Prof, Sever, Peter, Prof

“…Summary Background In blinded randomised controlled trials, statin therapy has been associated with few adverse events (AEs). By contrast, in observational…”
Get full text

Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy by Olsen, Michael H, Wachtell, Kristian, Ibsen, Hans, Lindholm, Lars, Kjeldsen, Sverre E, Omvik, Per, Nieminen, Markku S, Dahlöf, Björn, Okin, Peter M, Devereux, Richard B

“…AIMTo investigate whether in-treatment measurements of subclinical organ damage (SOD) assessed by elevated urine albumin/creatinine ratio (UACR) or…”
Get full text

Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients by Jamerson, Kenneth, Weber, Michael A, Bakris, George L, Dahlöf, Björn, Pitt, Bertram, Shi, Victor, Hester, Allen, Gupte, Jitendra, Gatlin, Marjorie, Velazquez, Eric J

“…The optimal combination drug therapy for treatment of hypertension is not established, although current U.S. guidelines recommend inclusion of a diuretic. This…”
Get full text

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial by Bakris, George L, Dr, Prof, Sarafidis, Pantelis A, MD, Weir, Matthew R, Prof, Dahlöf, Björn, Prof, Pitt, Bertram, Prof, Jamerson, Kenneth, MD, Velazquez, Eric J, MD, Staikos-Byrne, Linda, PhD, Kelly, Roxzana Y, MS, Shi, Victor, MD, Chiang, Yann-Tong, PhD, Weber, Michael A, Prof

“…Summary Background The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that…”
Get full text

Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy by SOLOMON, Scott D, APPELBAUM, Evan, MANNING, Warren J, VERMA, Anil, BERGLUND, Tommy, LUKASHEVICH, Valentina, CHERIF PAPST, Cheraz, SMITH, Beverly A, DAHLÖF, Bjom

“…Left ventricular (LV) hypertrophy, a marker of cardiac end-organ damage, is associated with an increased risk of cardiovascular morbidity and mortality…”
Get full text

Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension by Chapman, Neil, Dobson, Joanna, Wilson, Sarah, Dahlöf, Björn, Sever, Peter S, Wedel, Hans, Poulter, Neil R

“…Spironolactone is recommended as fourth-line therapy for essential hypertension despite few supporting data for this indication. We evaluated the effect among…”
Get full text

Effect of Lower On-Treatment Systolic Blood Pressure on the Risk of Atrial Fibrillation in Hypertensive Patients by Okin, Peter M, Hille, Darcy A, Larstorp, Anne Cecilie K, Wachtell, Kristian, Kjeldsen, Sverre E, Dahlöf, Björn, Devereux, Richard B

“…ABSTRACT—There is a well-established association between hypertension and atrial fibrillation (AF); indeed, even upper normal systolic blood pressures (SBP)…”
Get full text

Direct Angiotensin II Type 2 Receptor Stimulation Acts Anti-Inflammatory Through Epoxyeicosatrienoic Acid and Inhibition of Nuclear Factor κB by Rompe, Franziska, Artuc, Metin, Hallberg, Anders, Alterman, Mathias, Ströder, Katja, Thöne-Reineke, Christa, Reichenbach, Anne, Schacherl, Jens, Dahlöf, Björn, Bader, Michael, Alenina, Natalia, Schwaninger, Markus, Zuberbier, Torsten, Funke-Kaiser, Heiko, Schmidt, Cosima, Schunck, Wolf-Hagen, Unger, Thomas, Steckelings, U Muscha

“…Angiotensin II type 2 (AT2) receptors can be regarded as an endogenous repair system, because the AT2 receptor is upregulated in tissue damage and mediates…”
Get full text

Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study by Sawada, Takahisa, Yamada, Hiroyuki, Dahlöf, Björn, Matsubara, Hiroaki

“…Aims The objective was to assess the add-on effect of valsartan on top of the conventional treatment for high-risk hypertension in terms of the morbidity and…”
Get full text

The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor by Stanger, Livia, Yamaguchi, Adriana, Yalavarthi, Pooja, Lambert, Sylviane, Gilmore, Devin, Rickenberg, Andrew, Luke, Catherine, Kumar, Kiran, Obi, Andrea T., White, Andrew, Bergh, Niklas, Dahlof, Bjorn, Holinstat, Michael

“…•CS585 is a novel prostacyclin receptor agonist that effectively inhibits integrin activation, granule secretion, and aggregation.•CS585 is a highly potent and…”
Get full text

Change in Pulse Pressure/Stroke Index in Response to Sustained Blood Pressure Reduction and Its Impact on Left Ventricular Mass and Geometry Changes: the Life Study by Palmieri, Vittorio, Bella, Jonathan N., Gerdts, Eva, Wachtell, Kristian, Papademetriou, Vasilios, Nieminen, Markku S., Dahlöf, Björn, Devereux, Richard B.

“…Background In cross-sectional data in hypertensive subjects, brachial pulse pressure (PP)/Doppler stroke index (SVi), (PP/SVi) correlates weakly but…”
Get full text

Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA) by Sever, Peter S, Poulter, Neil R, Dahlöf, Björn, Wedel, Hans, Collins, Rory, Beevers, Gareth, Caulfield, Mark, Kjeldsen, Sverre E, Kristinsson, Arni, McInnes, Gordon T, Mehlsen, Jesper, Nieminen, Markku, O'Brien, Eoin, Ostergren, Jan

“…OBJECTIVE:--This study aims to establish the benefits of lowering cholesterol in diabetic patients with well-controlled hypertension and average/below-average…”
Get full text

Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes by Weber, Michael A., MD, Bakris, George L., MD, Jamerson, Kenneth, MD, Weir, Matthew, MD, Kjeldsen, Sverre E., MD, Devereux, Richard B., MD, Velazquez, Eric J., MD, Dahlöf, Björn, MD, Kelly, Roxzana Y., MS, Hua, Tsushung A., PhD, Hester, Allen, PhD, Pitt, Bertram, MD

“…Objectives The aim of this study was to determine which combination therapy in patients with hypertension and diabetes most effectively decreases…”
Get full text